Generic Name: obinutuzumab
Applies to obinutuzumab: intravenous solution
In addition to its needed effects, some unwanted effects may be caused by obinutuzumab (the active ingredient contained in Gazyva). In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking obinutuzumab, check with your doctor or nurse immediately:
Some of the side effects that can occur with obinutuzumab may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:


Applies to obinutuzumab: intravenous solution
The most frequently reported side effects included infusion reactions, neutropenia, thrombocytopenia, anemia, pyrexia, cough, and musculoskeletal disorders.[Ref]
Frequency not reported: Worsening of preexisting cardiac conditions with fatalities, atrial fibrillation[Ref]
Very common (10% or more): Neutropenia (40%), thrombocytopenia (15%), anemia (12%)Common (1% to 10%): Leukopenia (7%)[Ref]
Very common (10% or more): AST (SGOT) increased (28%), ALT (SGPT) increased (25%)[Ref]
Very common (10% or more): Hypocalcemia (32%), hyperkalemia (31%), hyponatremia (29%), hypoalbuminemia (22%), alkaline phosphatase increased (16%), hypokalemia (13%)Common (1% to 10%): Grade 3 or 4 tumor lysis syndrome (2%)[Ref]
Very common (10% or more): Musculoskeletal disorders including pain (17%)[Ref]
Frequency not reported: Progressive multifocal leukoencephalopathy[Ref]
Very common (10% or more): Infusion related reactions (69%), pyrexia (10%)[Ref]
Very common (10% or more): Creatinine increased (30%)[Ref]
Very common (10% or more): Cough (10%)[Ref]
Very common (10% or more): Positive test for anti-obinutuzumab (the active ingredient contained in Gazyva) antibodies (13%)Common (1% to 10%): Infection (9%)Frequency not reported: Hepatitis B reactivation[Ref]
1. "Product Information. Gazyva (obinutuzumab)." Genentech, South San Francisco, CA. 
2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):
3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
Not all side effects for Gazyva may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Back pain
black, tarry stools
bleeding gums
blood in the urine or stools
chest tightness
chills
cough or hoarseness
fever
flushing
headache
lower back or side pain
nausea and vomiting
painful or difficult urination
pale skin
pinpoint red spots on the skin
sore throat
trouble breathing
troubled breathing with exertion
ulcers, sores, or white spots in the mouth
unusual bleeding or bruising
unusual tiredness or weakness


Joint pain, stiffness, or swelling
lower back, side, or stomach pain
swelling of the feet or lower legs


Blurred vision
confusion
convulsions
dark urine
dizziness
drowsiness
general tiredness and weakness
headache
light-colored stools
upper right abdominal or stomach pain
yellow eyes and skin


Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

